Drug intelligence / Profile preview

VT-5006

Development stage: Phase 1
Lead developer: Vertero Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

VT-5006 is a first-in-class, gut-selective small molecule designed to delay the onset, slow the progression, and preserve the quality of life for patients with Parkinson's disease. It targets a validated peripheral driver of the disease, specifically focusing on the gastrointestinal tract to address protein aggregation and inflammation implicated in Parkinson's disease. VT-5006 is being developed by Vertero Therapeutics, formerly known as Axial Therapeutics, as part of their approach to treating neurodegenerative diseases by targeting peripheral drivers beyond the brain.

Targets

CsgA (Curli major subunit CsgA)

Beyond the preview

Go deeper on VT-5006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VT-5006.

Explore the full profile